Last reviewed · How we verify
Leuprolide flare
At a glance
| Generic name | Leuprolide flare |
|---|---|
| Also known as | Lupron. |
| Sponsor | Wake Forest University Health Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer (PHASE2)
- Maximal Stimulation and Delayed Fertilization for Diminished Ovarian Reserve: a Randomized Pilot Study (PHASE4)
- Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624 (PHASE3)
- A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer (PHASE3)
- Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer (PHASE2)
- Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol (PHASE4)
- R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer (PHASE2)
- Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Leuprolide flare CI brief — competitive landscape report
- Leuprolide flare updates RSS · CI watch RSS
- Wake Forest University Health Sciences portfolio CI